Atrophic Macular Degeneration
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Atrophic Macular Degeneration is an early-stage landscape with 5 programs across 3 companies. The most active players are AstraZeneca, Apellis Pharmaceuticals, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 4 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Modality Breakdown
80%
Small molecule
4 of 5 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 100% of 5 pipeline programs.
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)